Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy

Journal of Clinical Virology

Volumn 60, Issue 2, 2014, Pages 127-132

  Gantt, Soren ^a,b,c,d   Cattamanchi, Ashok ^a   Krantz, Elizabeth ^c   Magaret, Amalia ^a,c   Selke, Stacy ^a   Kuntz, Steven R ^a   Huang, Meei Li ^a   Corey, Lawrence ^a,c   Wald, Anna ^a,c   Casper, Corey ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; Human herpesvirus 8; Kaposi sarcoma; Protease inhibitor

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; ATAZANAVIR; DIDANOSINE PLUS LAMIVUDINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS DNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; COMPLICATION; FEMALE; GENETICS; HERPES VIRUS INFECTION; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; NASOPHARYNX; PROCEDURES; UNITED STATES; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; NASOPHARYNX; PROSPECTIVE STUDIES; VIRAL LOAD; VIRUS SHEDDING; WASHINGTON; YOUNG ADULT;

EID: 84900303076     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.03.002     Document Type: Article

References (55)

1. Eltom M.A., Jemal A., Mbulaiteye S.M., Devesa S.S., Biggar R.J. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002, 94:1204-1210.
2. Maurer T., Ponte M., Leslie K. HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007, 357:1352-1353.
3. Krown S.E., Lee J.Y., Dittmer D.P. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008, 358:535-536. author reply 36.
4. Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 2011, 62:157-170.
5. Dupont C., Vasseur E., Beauchet A., Aegerter P., Berthe H., de Truchis P., et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 2000, 14:987-993.
6. Dupin N., Rubin De Cervens V., Gorin I., Calvez V., Pessis E., Grandadam M., et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Dermatol 1999, 140:875-881.
7. Lebbe C., Blum L., Pellet C., Blanchard G., Verola O., Morel P., et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998, 12:F45-F49.
8. Bihl F., Mosam A., Henry L.N., Chisholm J.V., Dollard S., Gumbi P., et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS 2007, 21:1245-1252.
9. Nguyen H.Q., Magaret A.S., Kitahata M.M., Van Rompaey S.E., Wald A., Casper C. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 2008, 22:937-945.
10. Whitby D., Howard M.R., Tenant-Flowers M., Brink N.S., Copas A., Boshoff C., et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 1995, 346:799-802.
11. Lorenzen T., Albrecht D., Paech V., Meyer T., Hoffmann C., Stoehr A., et al. HHV-8 DNA in blood and the development of HIV-associated Kaposi's sarcoma in the era of HAART--a prospective evaluation. Eur J Med Res 2002, 7:283-286.
12. Campbell T.B., Borok M., Gwanzura L., MaWhinney S., White I.E., Ndemera B., et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000, 14:2109-2116.
13. Cannon M.J., Dollard S.C., Black J.B., Edlin B.R., Hannah C., Hogan S.E., et al. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003, 17:215-222.
14. Broccolo F., Bossolasco S., Careddu A.M., Tambussi G., Lazzarin A., Cinque P. Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 2002, 9:1222-1228.
15. Gill J., Bourboulia D., Wilkinson J., Hayes P., Cope A., Marcelin A.G., et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002, 31:384-390.
16. Engels E.A., Biggar R.J., Marshall V.A., Walters M.A., Gamache C.J., Whitby D., et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 2003, 17:1847-1851.
17. Pellet C., Chevret S., Blum L., Gauville C., Hurault M., Blanchard G., et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001, 117:858-863.
18. Leao J.C., Kumar N., McLean K.A., Porter S.R., Scully C.M., Swan A.V., et al. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. J Med Virol 2000, 62:416-420.
19. Borok M., Fiorillo S., Gudza I., Putnam B., Ndemera B., White I.E., et al. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe. Clin Infect Dis 2010.
20. Wilkinson J., Cope A., Gill J., Bourboulia D., Hayes P., Imami N., et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy. J Virol 2002, 76:2634-2640.
21. Sirianni M.C., Vincenzi L., Topino S., Giovannetti A., Mazzetta F., Libi F., et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur J Immunol 2002, 32:2711-2720.
22. Barillari G., Ensoli B. Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma. Clin Microbiol Rev 2002, 15:310-326.
23. Varthakavi V., Smith R.M., Deng H., Sun R., Spearman P. Human immunodeficiency virus type-1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus through induction of KSHV Rta. Virology 2002, 297:270-280.
24. Bani-Sadr F., Fournier S., Molina J.M. Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. AIDS 2003, 17:1580-1581.
25. Leitch H., Trudeau M., Routy J.P. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials 2003, 4:107-114.
26. Rey D., Schmitt M.P., Partisani M., Hess-Kempf G., Krantz V., de Mautort E., et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001, 27:459-462.
27. Portsmouth S., Stebbing J., Gill J., Mandalia S., Bower M., Nelson M., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003, 17:F17-F22.
28. Martinez V., Caumes E., Gambotti L., Ittah H., Morini J.P., Deleuze J., et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006, 94:1000-1006.
29. Crum-Cianflone N.F., Hullsiek K.H., Marconi V., Weintrob A., Ganesan A., Barthel R.V., et al. The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2009, 51:305-309.
30. Gantt S., Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011, 24:295-301.
31. Bernstein W.B., Dennis P.A. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 2008, 3:666-675.
32. Chow W.A., Jiang C., Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10:61-71.
33. Gantt S., Casper C., Ambinder R.F. Insights into the broad cellular effects of nelfinavir and the hiv protease inhibitors supporting their role in cancer treatment and prevention. Curr Opin Oncol 2013, 25.
34. Gantt S., Carlsson J., Ikoma M., Gachelet E., Gray M., Geballe A.P., et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011, 55:2696-2703.
35. Gustafson E.A., Schinazi R.F., Fingeroth J.D. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 2000, 74:684-692.
36. Lock M.J., Thorley N., Teo J., Emery V.C. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 2002, 49:359-366.
37. Corey L., Brodie S., Huang M.L., Koelle D.M., Wald A. HHV-8 infection: a model for reactivation and transmission. Rev Med Virol 2002, 12:47-63.
38. Casper C., Redman M., Huang M.L., Pauk J., Lampinen T.M., Hawes S.E., et al. HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. J Acquir Immune Defic Syndr 2004, 35:233-238.
39. Ryncarz A.J., Goddard J., Wald A., Huang M.L., Roizman B., Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999, 37:1941-1947.
40. Johnston C., Orem J., Okuku F., Kalinaki M., Saracino M., Katongole-Mbidde E., et al. Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. PLoS ONE 2009, 4:e 4222.
41. Casper C., Krantz E., Taylor H., Dalessio J., Carrell D., Wald A., et al. Assessment of a combined testing strategy for detection of antibodies to human herpesvirus 8 (HHV-8) in persons with Kaposi's sarcoma, persons with asymptomatic HHV-8 infection, and persons at low risk for HHV-8 infection. J Clin Microbiol 2002, 40:3822-3825.
42. Pauk J., Huang M.L., Brodie S.J., Wald A., Koelle D.M., Schacker T., et al. Mucosal shedding of human herpesvirus 8 in men. N Engl J Med 2000, 343:1369-1377.
43. Casper C., Krantz E., Selke S., Kuntz S.R., Wang J., Huang M.L., et al. Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis 2007, 195:30-36.
44. Diggle P., Heagerty P., Liang K.Y., Zeger S. Analysis of longitudinal data 2002, Oxford University Press, New York. 2nd ed.
45. Hernan M.A., Brumback B., Robins J.M. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000, 11:561-570.
46. Casper C., Krantz E.M., Corey L., Kuntz S.R., Wang J., Selke S., et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008, 198:23-30.
47. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010, 120:939-949.
48. Sgadari C., Barillari G., Toschi E., Carlei D., Bacigalupo I., Baccarini S., et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002, 8:225-232.
49. Pati S., Pelser C.B., Dufraine J., Bryant J.L., Reitz M.S., Weichold F.F. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002, 99:3771-3779.
50. Kalu N., Shirley C., Ambinder R.F. ER stress activates lytic gene expression in KSHV associated tumor cell lines. International Congress on Oncogenic Herpesviruses and Associated Diseases. Philadelphia, PA. Infect Agents Cancer 2012.
51. Grabar S., Abraham B., Mahamat A., Del Giudice P., Rosenthal E., Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006, 24:3408-3414.
52. Conant M.A., Opp K.M., Poretz D., Mills R.G. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997, 11:1300-1301.
53. Stebbing J., Portsmouth S., Nelson M., Mandalia S., Kandil H., Alexander N., et al. The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. Int J Cancer 2004, 108:631-633.
54. Ridolfo A.L., Corbellino M., Tosca N., Capelletti A., Scalamogna C., Galli M., et al. Is switching protease inhibitor-based effective antiretroviral therapy safe in patients with AIDS-associated Kaposi's sarcoma?. AIDS 2004, 18:1224-1226.
55. Monini P., Sgadari C., Grosso M.G., Bellino S., Di Biagio A., Toschi E., et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009, 23:534-538.